General description
ABT-418 is an α4β2 agonist of nicotinic receptors.
Application
ABT-418 [(S)-3-methyl-5-(1 methyl-2-pyrrolidinyl)isoxazole hydrochloride] is a novel neuronal nicotinic acetylcholine receptor (nAChR) ligand with cognitive enhancing and anxiolytic-like activity 3- to 10-fold more potent than (-)-nicotine in rodents. ABT-418 hydrochloride has been used to study new therapeutic approaches for the treatment of Alzheimer′s disease.
ABT-418 hydrochloride has been used as a nicotinic acetylcholine receptor (nAChR) agonist to test its effect on spatial memory improvement in attention deficit hyperactivity disorder (ADHD) rat model
Biochem/physiol Actions
Neuronal nicotinic acetylcholine receptor agonist with cognition enhancing and anxiolytic activities.
Features and Benefits
This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Subject to U.S. Patent No. 5409946 and sold under license from Abbott Laboratories.
| assay | ≥98% (HPLC) |
| form | powder |
| storage condition | desiccated |
| solubility | H2O: soluble 15 mg/mL |
| originator | Abbott |
| SMILES string | Cl.CN1CCC[C@H]1c2cc(C)no2 |
| InChI | 1S/C9H14N2O.ClH/c1-7-6-9(12-10-7)8-4-3-5-11(8)2;/h6,8H,3-5H2,1-2H3;1H/t8-;/m0./s1 |
| InChI key | VOXHERKWAIEJQF-QRPNPIFTSA-N |
